Afinitor gains KFDA approval to treat patients with advanced pancreatic neuroendocrine tumors

Novartis Korea announced Monday that the Korea Food and Drug Administration has approved Afinitor (everolimus) tablets for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumors (NET) of pancreatic origin in adults with progressive disease.

The approval was based on Phase III data from the largest clinical trial to date in advanced pancreatic NE...